HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy
The top lawyer at the U.S. Health and Human Services (HHS) department told drug manufacturer Eli Lilly and Co. in a letter dated Sept. 21 and made public this morning that it “cannot and should not view the absence of any questions from the government” about Lilly’s decision to dramatically scale back 340B pricing on its products “as somehow endorsing Lilly’s policy.”
HHS General Counsel Robert Charrow was responding to a Sept. 8 letter from Lilly asking whether the company would be subject to sanctions due to its Sept. 1 decision to limit 340B pricing on virtually all of its products to covered entities and their child sites only, or to just one contract pharmacy per entity for those without an in-house pharmacy. Lilly also imposed strict conditions on 340B covered entities on charges and reimbursement for Lilly insulin.
HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy The top lawyer at the U.S. Health and Human Services (HHS) department told drug manufacturer Eli Lilly and Co. in a letter dated Sept. 21 and made public […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
